Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTXR$0.53-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
SEPTEMBER 30, 2024 AND 2023
| 2024 | 2023 | |
|---|---|---|
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $3,251,880 | $26,480,928 |
| Inventory | 8,268,766 | — |
| Prepaid expenses | 2,700,000 | 7,889,506 |
| Total Current Assets | 14,220,646 | 34,370,434 |
| Property and equipment, net | — | 1,432 |
| Operating lease right-of-use asset, net | 246,247 | 454,426 |
| Other Assets: | ||
| Deposits | 38,062 | 38,062 |
| In-process research and development | 92,800,000 | 59,400,000 |
| Goodwill | 9,346,796 | 9,346,796 |
| Total Other Assets | 102,184,858 | 68,784,858 |
| Total Assets | $116,651,751 | $103,611,150 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities: | ||
| Accounts payable | $4,927,211 | $2,927,334 |
| License payable | 28,400,000 | — |
| Accrued expenses | 17,027 | 476,300 |
| Accrued compensation | 2,229,018 | 2,156,983 |
| Operating lease liability | 241,547 | 218,380 |
| Total Current Liabilities | 35,814,803 | 5,778,997 |
| Deferred tax liability | 6,713,800 | 6,137,800 |
| Operating lease liability – non current | 21,318 | 262,865 |
| Total Liabilities | 42,549,921 | 12,179,662 |
| Commitments and Contingencies | ||
| Stockholders’ Equity: | ||
| Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively | 7,247 | 6,354 |
| Additional paid-in capital | 271,440,421 | 253,056,133 |
| Accumulated deficit | (201,370,218) | (162,231,379) |
| Total Citius Pharmaceuticals, Inc. Stockholders’ Equity | 70,077,450 | 90,831,108 |
| Non-controlling interest | 4,024,380 | 600,380 |
| Total Equity | 74,101,830 | 91,431,488 |
| Total Liabilities and Equity | $116,651,751 | $103,611,150 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.